News

SwanBio previously presented positive preclinical data at the ESGCT 2021 meeting.

The director of the hemostasis and thrombosis program at Children’s Hospital Los Angeles discussed the ATLAS-INH trial.

The director of the Pediatric Hemophilia and Coagulation Disorders Program at CS Mott Children’s Hospital discussed challenges in hemophilia A and B.

The approval was based on findings from the phase 2 KarMMa trial and the phase 1 Study CRB-401 trial.

The positive news is countered by a report of a patient death in Taysha’s gene therapy program for GM2 gangliosidosis.

The FDA has approved the prescribing label update based on data from a new safety management cohort of the phase 1/2 ZUMA-1 trial.

The clinical trial of 4D-150 expects to enroll around 60 participants with wet AMD.

The director of the Melanoma Program at Cedars-Sinai Medical Center discussed the efficacy of TIL therapy following immunotherapy in advanced melanoma.

Both the Sirius and Celeste phase 2/3 trials are evaluating QR-421a.

Review top news and interview highlights from the week ending January 28, 2022.

Exciting new therapies are on the horizon for inherited retinal disease. We’ve compiled a quick snapshot of promising investigative therapies.

The latest hold on MB-207 follows a similar hold on another XSCID therapy, MB-107.

The director of the Melanoma Program at Cedars-Sinai Medical Center discussed evaluation criteria for TIL therapy in melanoma.

The clinical professor of medicine, Helen Diller Family Comprehensive Cancer Center, UCSF, discussed data from both the CARTITUDE-1 and CARTITUDE-2 studies.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in gene and cell therapies.

The medical director of Bone Marrow Transplantation and Immune Deficiency at Cincinnati Children's discussed data on ARU-1801 presented at ASH 2021.

The SURPASS-2 trial will run parallel to the ongoing SURPASS trial.

The hematologist/oncologist from Mayo Clinic discussed advantages of Tmod cell therapy in solid tumors.

Investigators from IRCCS San Raffaele analyzed results from a phase 1/2 study on atidarsagene autotemcel.

Dolores Schendel, PhD, chief executive and chief scientific officer, Medigene, discussed MDG1011 and Medigene’s future research and targets.

The BASECAMP-1 study is identifying patients for future use of Tmod CAR T-cell therapies.

The T-cell therapy targets 6 tumor-associated antigens that are highly expressed in pancreatic cancer.

The associate professor from Fred Hutchinson Cancer Research Center discussed the methods utilized in an ongoing phase 1/2 trial evaluating MB-106.

Positive data from a phase 1 trial were presented at the 2021 ASCO meeting.

The director of the hemostasis and thrombosis program at Children’s Hospital Los Angeles discussed advantages of the siRNA therapeutic.

Review top news and interview highlights from the week ending January 21, 2022.

The FDA and Gamida Cell have reached a consensus on the comparability of omidubicel manufactured at different sites.

Data from the phase 2 QUILT-88 study were presented at the 2022 ASCO GI symposium.